Published in Blood on August 01, 1996
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant (2009) 1.68
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood (2010) 1.41
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood (2012) 1.35
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood (2011) 1.26
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One (2012) 1.20
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant (2013) 1.12
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood (2009) 1.11
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol (2007) 1.07
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol (2005) 1.05
Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases. World J Gastroenterol (2009) 1.03
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol (2009) 1.02
Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica (2012) 0.99
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis (2011) 0.98
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res (2013) 0.95
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res (2010) 0.95
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia (2015) 0.93
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics (2007) 0.93
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2013) 0.93
Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag (2012) 0.93
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood (2014) 0.90
How to manage the transplant question in myelofibrosis. Blood Cancer J (2012) 0.89
Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol (2009) 0.89
Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc (2009) 0.88
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics (2011) 0.87
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant (2010) 0.87
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica (2016) 0.84
Myelofibrosis 2012: it's complicated. Ther Adv Hematol (2012) 0.83
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant (2014) 0.81
Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study. Eur J Nucl Med Mol Imaging (2015) 0.80
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience. Mediterr J Hematol Infect Dis (2010) 0.79
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica (2010) 0.79
Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis. Case Rep Hematol (2013) 0.79
Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin Hematol (2014) 0.79
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant (2015) 0.78
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics (Sao Paulo) (2013) 0.78
Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Rev Hematol (2010) 0.78
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis. Haematologica (2016) 0.77
Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. PLoS One (2015) 0.77
[Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis]. Pathologe (2012) 0.76
Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy. Case Rep Hematol (2015) 0.76
Relevance of prognostic features in myeloid metaplasia to selection of patients for bone marrow transplantation. Blood (1997) 0.75
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leuk Suppl (2012) 0.75
Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease. Hematol Oncol Clin North Am (2014) 0.75
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res (2016) 0.75
Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments. PLoS One (2016) 0.75
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol (2016) 0.75
Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report. Balkan J Med Genet (2014) 0.75
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS One (2016) 0.75
Factors affecting prognosis in myelofibrosis. F1000 Med Rep (2009) 0.75
The sequence of the human genome. Science (2001) 101.55
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A (2003) 14.01
Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A (1992) 13.77
Flagellar rotation and the mechanism of bacterial motility. Nature (1974) 10.38
Analysis of the nucleotide sequence of an invertible controlling element. Proc Natl Acad Sci U S A (1980) 5.92
Genetic analysis of flagellar mutants in Escherichia coli. J Bacteriol (1973) 4.98
Identification of polypeptides necessary for chemotaxis in Escherichia coli. J Bacteriol (1977) 4.84
Characterization of Escherichia coli flagellar mutants that are insensitive to catabolite repression. J Bacteriol (1974) 4.84
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol (2004) 4.78
Regulation of lateral flagella gene transcription in Vibrio parahaemolyticus. J Bacteriol (1986) 4.52
Chemotaxis in Escherichia coli: methylation of che gene products. Proc Natl Acad Sci U S A (1977) 4.34
Recombinational switch for gene expression. Science (1977) 4.31
Phase variation: genetic analysis of switching mutants. Cell (1980) 4.05
Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg (2006) 3.98
Operon controlling motility and chemotoxis in E. coli. Nature (1976) 3.95
Structure and function of the Saccharomyces cerevisiae CDC2 gene encoding the large subunit of DNA polymerase III. EMBO J (1989) 3.93
Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood (2000) 3.88
Mesenteric cysts. Toward less confusion? Dig Surg (2000) 3.78
Genetic analysis of bacteriophage Mu-induced flagellar mutants in Escherichia coli. J Bacteriol (1973) 3.55
Measuring gene expression with light. Science (1985) 3.47
The T cell receptor beta chain genes are located on chromosome 6 in mice and chromosome 7 in humans. Cell (1984) 3.34
The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol (1999) 3.22
The identification of the mot gene product with Escherichia coli-lambda hybrids. Proc Natl Acad Sci U S A (1976) 3.20
Synthesis of mot and che gene products of Escherichia coli programmed by hybrid ColE1 plasmids in minicells. J Bacteriol (1977) 3.05
Mitochondrial splicing requires a protein from a novel helicase family. Nature (1989) 3.03
Phase variation in Salmonella: genetic analysis of a recombinational switch. Proc Natl Acad Sci U S A (1979) 3.02
Regulation of gene expression by site-specific inversion. Cell (1978) 2.97
Phase variation: evolution of a controlling element. Science (1980) 2.96
Purification and thermal stability of intact Bacillus subtilis flagella. J Bacteriol (1971) 2.87
Association of mitochondria with microtubules in cultured cells. Proc Natl Acad Sci U S A (1978) 2.85
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med (2001) 2.81
Bacterial chemotaxis. Annu Rev Physiol (1982) 2.74
Detection of human herpesvirus 8 and human T-cell lymphotropic virus type 1 sequences in Kaposi sarcoma. Arch Dermatol (1997) 2.71
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 2.71
Abdominal lymphangioma in adults and children. Br J Surg (1998) 2.70
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol (2013) 2.70
Polymerization of Ftsz, a bacterial homolog of tubulin. is assembly cooperative? J Biol Chem (2001) 2.62
[Letter: Idiopathic hemochromatosis associated with HL-A 3 tissular antigen]. Nouv Presse Med (1975) 2.57
The engrailed locus of Drosophila: in situ localization of transcripts reveals compartment-specific expression. Cell (1985) 2.55
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood (1994) 2.51
Cloning and expression of the flagellar hook gene on hybird plasmids in minicells. Nature (1977) 2.50
Genes for the hook-basal body proteins of the flagellar apparatus in Escherichia coli. J Bacteriol (1978) 2.44
The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD. J Mol Biol (1995) 2.38
Bacterial bioluminescence: isolation and expression of the luciferase genes from Vibrio harveyi. Science (1982) 2.38
The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest (1995) 2.37
Characterization of lambda Escherichia coli hybrids carrying chemotaxis genes. J Bacteriol (1977) 2.37
DNA sequence adjacent to flagellar genes and evolution of flagellar-phase variation. J Bacteriol (1983) 2.30
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol (2000) 2.30
Transposon mutagenesis of marine Vibrio spp. J Bacteriol (1984) 2.29
An evaluation of the polymerase chain reaction amplicor Chlamydia trachomatis in male urine and female urogenital specimens. Sex Transm Dis (1994) 2.26
Randomized clinical trial of laparoendoscopic single-site versus conventional laparoscopic cholecystectomy. Br J Surg (2011) 2.25
Randomized clinical trial of mechanical bowel preparation versus no preparation before elective left-sided colorectal surgery. Br J Surg (2005) 2.24
Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol (1996) 2.23
Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras. Proc Natl Acad Sci U S A (1992) 2.23
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Identification of the structural gene for the hook subunit protein of Escherichia coli flagella. J Bacteriol (1978) 2.20
Identification in situ and dynamics of bacteria on limnetic organic aggregates (lake snow). Appl Environ Microbiol (1996) 2.20
Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut (1976) 2.15
Sensory transducers of E. coli are encoded by homologous genes. Cell (1981) 2.14
High-resolution restriction maps of bacterial artificial chromosomes constructed by optical mapping. Proc Natl Acad Sci U S A (1998) 2.10
Clinicoradiological score for predicting the risk of strangulated small bowel obstruction. Br J Surg (2010) 2.07
Significance of bacteriophages for controlling bacterioplankton growth in a mesotrophic lake. Appl Environ Microbiol (1995) 2.03
Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant (2008) 2.03
Perforation of the inferior vena cava with aortic and vertebral penetration by a suprarenal Greenfield filter. Radiology (1989) 2.02
Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med (1977) 2.01
The regulation of flagellar formation and function. J Supramol Struct (1974) 2.01
High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol (1995) 2.00
VE-cadherin antibody accelerates neutrophil recruitment in vivo. J Cell Sci (1997) 2.00
VirA, a coregulator of Ti-specified virulence genes, is phosphorylated in vitro. J Bacteriol (1990) 1.98
Biotechnology awareness study, Part 2: Meeting the information needs of biotechnologists. Bull Med Libr Assoc (1991) 1.96
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes (1993) 1.95
Enzymatic cross-linking of involucrin and other proteins by keratinocyte particulates in vitro. Cell (1985) 1.94
Management of bleeding pseudoaneurysms in patients with pancreatitis. Br J Surg (1999) 1.92
Synthesis of bacterial flagella. I. Requirement for protein and ribonucleic acid synthesis during flagellar regeneration in Bacillus subtilis. J Bacteriol (1968) 1.91
Efficacy of capsaicin in the treatment of acne in one case: new pathophysiological perspectives. J Eur Acad Dermatol Venereol (2009) 1.90
Participation of membrane-associated proteins in the formation of the cross-linked envelope of the keratinocyte. Cell (1984) 1.85
Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis (2001) 1.84
Perianal findings in prepubertal children selected for nonabuse: a descriptive study. Child Abuse Negl (1989) 1.81
Antibodies to the alpha q subfamily of guanine nucleotide-binding regulatory protein alpha subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones. J Biol Chem (1991) 1.80
Bouveret's syndrome: management and strategy of a rare cause of gastric outlet obstruction. Digestion (2007) 1.79
Computed tomography in acute left colonic diverticulitis. Br J Surg (1997) 1.79
Chemotactic control of the two flagellar systems of Vibrio parahaemolyticus. J Bacteriol (1990) 1.78
Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol (1999) 1.77
Operative injury to the hepatic artery. Consequences of a biliary-enteric anastomosis and principles for rational management. Arch Surg (1996) 1.77
Genetic analysis of Escherichia coli K-12 region I flagellar mutants. J Bacteriol (1977) 1.76
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol (1997) 1.76
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol (2011) 1.75
Legumin Synthesis in Developing Cotyledons of Vicia faba L. Plant Physiol (1971) 1.74
Lipid A: chemical structure and biological activity. J Infect Dis (1973) 1.73
Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis (2003) 1.72
Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins. Neuron (1995) 1.70
Molecular characterization of the vir regulon of Agrobacterium tumefaciens: complete nucleotide sequence and gene organization of the 28.63-kbp regulon cloned as a single unit. Plasmid (1990) 1.70
Defense factors of vaginal lactobacilli. Am J Obstet Gynecol (2001) 1.68
KIN28, a yeast split gene coding for a putative protein kinase homologous to CDC28. EMBO J (1986) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Involvement of the yeast DNA polymerase delta in DNA repair in vivo. Genetics (1997) 1.65